DHR

TentativeAI Memo

Danaher

As of 2026-10-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

—

Key catalyst

Fourth-quarter underlying growth versus respiratory drag • 2026-12-31

Base target: $249 / p=50% prob

Biggest risk

Reported core growth was only 3% including respiratory revenue, versus 5.5% excluding it. The approximately 150-basis-point respiratory headwind in fourth-quarter guidance and acquisition integration could limit earnings follow-through. [#SEC-8K-2026-10-21]

Invalidation

Break below $195 or thesis failure.

What would change my mind?

Q3 adjusted EPS of $2.11 beat the reported $1.92 consensus, while management raised full-year adjusted EPS guidance. Subsequent October 22 target increases were reported for Citi ($230 to $270), TD Cowen ($255 to $270) and Stifel ($220 to $260); these are target revisions, not evidence that forward earnings estimates rose. [#SEC-8K-2026-10-21] Analyst revision record

Research note

Recommendation

—

Confidence

medium

As of

2026-10-26

Base target

$249

p=50%

Bull target

$270

p=30%

Bear target

$195

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 beat-and-raise follow-through
Masimo and StatLab integration
Q3 adjusted EPS of $2.11 beat the reported $1.92 consensus, while management raised full-year adjusted EPS guidance.

BearKey bullets

Masimo and StatLab integration and acquisition-financing returns remain execution risks; the prior baseline's pending-close framing is stale relative to the supplied October 2026 10-Q excerpts.
Respiratory testing remains a drag: fourth-quarter guidance implies roughly 3% total core growth versus 4%–5% excluding respiratory revenue.
[#SEC-8K-2026-10-21]

WatchKey bullets

Fourth-quarter underlying growth versus respiratory drag

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $249 (p=50%)

Target spread vs base: +8% / -22%

Scenario probabilities

Bull Target: $270 (p=30%)Base Target: $249 (p=50%)Bear Target: $195 (p=20%)

Commentary

The Q3 company release and reported analyst target raises support a positive thesis update from the May baseline. The reported $233.86 October 21 close had eased to the packet's $230.50 October 23 anchor, however, so the first-day reaction did not fully hold. Consensus revenue comparisons conflict across secondary sources; only the $1.92 EPS consensus is used. Forward-estimate revisions, options, short-interest and sufficient social coverage were not established; zero sentiment-field values indicate unavailable data, not neutral measurements. [#SEC-8K-2026-10-21] Price history

As of 2026-10-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 beat-and-raise follow-through
Masimo and StatLab integration

Scenarios

Bull Target (Scenario probability)

$270 / p=30% prob

Base Target (Scenario probability)

$249 / p=50% prob

Bear Target (Scenario probability)

$195 / p=20% prob

Analysis 2026-10-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Fourth-quarter underlying growth versus respiratory drag
Danaher forecasts fourth-quarter core revenue growth of 4%–5% excluding respiratory revenue, but about 3% including an approximately 150-basis-point respiratory headwind. Sustaining the stronger underlying trend while delivering the raised EPS range is the next operating test. [#SEC-8K-2026-10-21]
Prob 60.00% • Move 5.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Q3 beat-and-raise follow-through
2026-11-20
Danaher reported Q3 revenue of $6.6 billion, adjusted EPS of $2.11, 5.5% core growth excluding respiratory testing, and $1.6 billion of free cash flow. It raised 2026 adjusted EPS guidance to $8.57–$8.62 from $8.45–$8.60. The near-term test is whether the initial post-print advance holds; the October 23 anchor of $230.50 is below the reported October 21 close of $233.86. [#8-K-2026-10-21] [#SEC-8K-2026-10-21]
Prob 60% • Move 3% • Priced-in 65%

Long-term Catalysts

Months to a year

Masimo and StatLab integration
2027-12-31
The supplied October 2026 10-Q relationship-context excerpts identify Masimo as acquired on June 10 and StatLab as acquired on September 28. The forward issue is integration, Diagnostics growth and returns on acquisition spending—not regulatory closing, which the prior baseline still treated as pending. [#10-Q-2026-10-21]
Prob 55% • Move 7% • Priced-in 40%

Risks

Masimo and StatLab integration and acquisition-financing returns remain execution risks; the prior baseline's pending-close framing is stale relative to the supplied October 2026 10-Q excerpts.
Respiratory testing remains a drag: fourth-quarter guidance implies roughly 3% total core growth versus 4%–5% excluding respiratory revenue. [#SEC-8K-2026-10-21]
The October 2026 10-Q describes separate $5 billion revolving facilities scheduled to expire in April 2027 and August 2028. They are liquidity support, not evidence of those amounts being drawn; borrowing and leverage require separate monitoring. [#REL-7f5b33a5-dccc-402e-afac-aeaba141e916] [#REL-5788ba97-73a2-49da-95ac-657399fede5a] https://www.sec.gov/Archives/edgar/data/313616/000031361626000199/dhr-20260925.htm

Peers

Symbol	Summary
A	Agilent is a narrower comparator for analytical instruments and laboratory demand normalization.
TMO	Thermo Fisher is the closest large-cap operating comparator across life-science tools, bioprocessing and diagnostics.
WAT	Waters is a narrower analytical-instruments comparator; it is less useful for judging Danaher's diagnostics and acquisition mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-26

Loading AI feed…

Symbol

Summary

Agilent is a narrower comparator for analytical instruments and laboratory demand normalization.

TMO

Thermo Fisher is the closest large-cap operating comparator across life-science tools, bioprocessing and diagnostics.

WAT

Waters is a narrower analytical-instruments comparator; it is less useful for judging Danaher's diagnostics and acquisition mix.